Dual antithrombotic therapy for patients with chronic forms of atherosclerotic disease - new indication based on the results of the study COMPASS

Abstract

Patients with polyvascular involvement (chronic coronary syndromes, stroke conditions and peripheral atherosclerotic involvement) are at high risk of cardiovascular events and also at risk of limb amputation. Their antithrombotic treatment has so far been based on antiplatelet therapy - in monotherapy or dual therapy.

Based on the positive results of the COMPASS study, the combination of acetylsalicylic acid with oral anticoagulant rivaroxaban at a reduced dose (a so-called dual antithrombotic therapy) should also be reconsidered in this type of patient.

Keywords

• atherothrombosis
• antiplatelet therapy
• anticoagulant therapy
• dual antithrombotic therapy
• acetylsalicylic acid
• rivaroxaban
• coronary artery disease
• stroke